Interstitial Cystitis / Bladder Pain Syndrome
Conditions
Interventions
Healthy control group:None
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. IC/BPS Patient Group (SNM Treatment Cohort) Inclusion criteria: (1) Patients with a confirmed clinical diagnosis of IC/BPS, characterized by symptoms such as urinary frequency, urgency, dysuria, and discomfort in the suprapubic region, urethra, or perineum upon bladder filling. (2) Age between 18 and 80 years (inclusive). (3) Clinically assessed as having refractory IC/BPS and scheduled to receive either sacral neuromodulation (SNM) trial treatment or cystoscopic hydrodistention (first stage) in the Department of Urology, Beijing Hospital. 2. Healthy Control Group Inclusion criteria: (1) Age between 18 and 80 years (inclusive), frequency-matched to the patient group by age and sex. (2) No chronic pelvic pain or lower urinary tract symptoms. (3) No long-term special dietary patterns (e.g., extreme high-fat or ketogenic diet). (4) Agree to complete a dietary assessment (e.g., food frequency questionnaire).
Exclusion criteria
Exclusion criteria: 1. IC/BPS Patient Group (SNM Treatment Cohort) Exclusion criteria: (1) Presence of urinary tract bacterial infection, urolithiasis, or urinary tract tumor. (2) Presence of inflammatory bowel disease, irritable bowel syndrome, or other diseases that significantly affect intestinal function. (3) Use of systemic antibiotics within 3 months prior to enrollment. (4) Presence of severe mental disorders (e.g., schizophrenia) or active autoimmune diseases. (5) Presence of contraindications to SNM (e.g., implanted cardiac pacemaker) or being pregnant or lactating. (6) Presence of any other serious diseases or factors that, in the investigator's judgment, may affect the study results. 2. Healthy Control Group Exclusion criteria: (1) Presence of intestinal diseases or mental/psychiatric disorders that may affect gut microbiota or study indicators. (2) Use of systemic antibiotics, probiotics, or proton pump inhibitors within 3 months prior to enrollment. (3) Any known history of malignant tumor. (4) History of chronic constipation or chronic diarrhea. (5) Pregnant or lactating women. (6) Presence of any other health problems that, in the investigator's judgment, may affect the study results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fecal gut microbiota; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Analog Scale pain score;ICSI score;ICPI score;24-hour voiding diary;GAD-7 score;PHQ-9 score;Percentage of symptom improvement;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactLingfeng Meng
Beijing Hospital
Outcome results
None listed